HIV-1 Tat-dependent transactivation complex (Tat-TAR-P-TEFb complex)

The HIV-1 Tat-dependent transactivation complex is a multi-component ribonucleoprotein assembly essential for the efficient transcription of the HIV-1 proviral genome [1]. It primarily consists of the viral Trans-activator of transcription (Tat) protein, the host-derived Positive Transcription Elongation Factor b (P-TEFb) complex—comprising Cyclin-dependent kinase 9 (CDK9) and Cyclin T1—and the Trans-activation Response (TAR) RNA element [2]. In the absence of Tat, host RNA polymerase II initiates transcription at the viral long terminal repeat but stalls shortly after, resulting in truncated viral transcripts. Tat overcomes this by binding to the TAR hairpin and recruiting P-TEFb, which phosphorylates the RNA polymerase II C-terminal domain and negative elongation factors to promote productive elongation [3]. This complex is a critical therapeutic target because its activity is required for viral replication and the maintenance of the latent HIV reservoir [1]. Pharmacological strategies include using small-molecule inhibitors like Alvocidib to target the CDK9 subunit or developing compounds that disrupt the specific Tat-TAR-P-TEFb interaction [4]. However, achieving therapeutic selectivity is challenging because P-TEFb is also required for the transcription of many essential host genes [4]. Targeting this complex is a central component of "Block and Lock" strategies aimed at achieving a functional cure for HIV by permanently silencing the viral promoter [1].

Other names

Tat-TAR complexHIV-1 transcriptional transactivation complexTat-P-TEFb complexTat-TAR-P-TEFb ribonucleoprotein complex

Inhibition of the CDK9 kinase subunit of P-TEFb to prevent phosphorylation of RNA polymerase II and negative elongation factors, or disruption of the Tat-TAR-P-TEFb assembly.